Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone and myeloma]

P Ravaud1, C Roux

  • 1Clinique de rhumatologie, hôpital Cochin, Paris.

La Revue Du Praticien
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Multiple myeloma causes bone loss by increasing osteoclasts. Osteoclast activating factors and bisphosphonates are key in managing this bone disease and hypercalcemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended photo-induced endosome-like structures in giant vesicles promoted by block-copolymer nanocarriers.

Nanoscale·2018
Same author

Intrathoracic pancreatic herniation: A rare cause of acute pancreatitis.

Diagnostic and interventional imaging·2018
Same author

Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.

Seminars in arthritis and rheumatism·2018
Same author

Adult hypophosphatasia.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2018
Same author

Hybrid vesicles from lipids and block copolymers: Phase behavior from the micro- to the nano-scale.

Colloids and surfaces. B, Biointerfaces·2018
Same author

[Erratum to "Histoplasma capsulatum bone and joint infection" [Med. Mal. Infect. 47 (2017) 554-557]].

Medecine et maladies infectieuses·2017
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Bone Biology

Background:

  • Multiple myeloma involves plasmocyte proliferation in the bone marrow.
  • This proliferation leads to increased osteoclast activity and osteolysis (bone loss).
  • Osteoclast activating factors (OAFs) like IL-1 beta, IL-6, and TNF are implicated.

Purpose of the Study:

  • To investigate the mechanisms of osteolysis in multiple myeloma.
  • To evaluate the role of osteoclast activating factors in myeloma-induced bone disease.
  • To assess the efficacy of bisphosphonates in managing myeloma-related osteolysis and hypercalcemia.

Main Methods:

  • Analysis of osteoclast activity in relation to myeloma cells.
  • Identification and quantification of osteoclast activating factors (OAFs) produced by myeloma cells and their microenvironment.

Related Experiment Videos

  • Clinical evaluation of bisphosphonate treatment for hypercalcemia and osteolysis progression.

    • Main Results:

    • Osteolysis is directly correlated with an increased number of osteoclasts interacting with myeloma cells.
    • Myeloma cells and their microenvironment produce key OAFs, including IL-1 beta, IL-6, and TNF.
    • Bisphosphonates demonstrate effectiveness in managing hypercalcemia associated with myeloma.

    Conclusions:

    • Myeloma-induced osteolysis is mediated by increased osteoclast activity driven by OAFs.
    • Bisphosphonates are effective in treating hypercalcemia and are being evaluated for their potential to slow osteolysis progression in multiple myeloma patients.